Aarti Pharmalabs Receives US FDA Inspection Report for Unit-IV
Aarti Pharmalabs Limited announced the completion of a United States Food and Drug Administration (US FDA) inspection of its Unit-IV facility in Tarapur, Maharashtra, on March 27, 2026.The inspection concluded with the issuance of a Form 483, which included one observation noted as procedural in nature. Aarti Pharmalabs stated that corrective and preventive actions, along with compliance documentation, will be submitted to the US FDA within the designated timeframe.
The facility inspected was located at Plot No. E-50, 50/1, 59/1, MIDC, Tarapur, Tal. & District Palghar, Maharashtra - 401506. Aarti Pharmalabs’ stock symbol is AARTIPHARM on the National Stock Exchange.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.